Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Polarization-independent plasmonic subtractive color filtering in ultrathin Ag nanodisks with high transmission.

Hu XL, Sun LB, Zeng B, Wang LS, Yu ZG, Bai SA, Yang SM, Zhao LX, Li Q, Qiu M, Tai RZ, Fecht HJ, Jiang JZ, Zhang DX.

Appl Opt. 2016 Jan 1;55(1):148-52.

PMID:
26835634
2.

Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.

Bai SA, Xiang Q, Finn A.

Clin Ther. 2016 Feb;38(2):358-69. doi: 10.1016/j.clinthera.2015.12.016. Epub 2016 Jan 21.

PMID:
26804639
3.

Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.

Darpo B, Zhou M, Bai SA, Ferber G, Xiang Q, Finn A.

Clin Ther. 2016 Feb;38(2):315-26. doi: 10.1016/j.clinthera.2015.12.004. Epub 2015 Dec 31.

PMID:
26749217
4.

Reliable and Sensitive Detection of Acidovorax citrulli in Cucurbit Seed Using a Padlock-Probe-Based Assay.

Tian Y, Zhao Y, Bai S, Walcott RR, Hu B, Liu F.

Plant Dis. 2013 Jul;97(7):961-966. doi: 10.1094/PDIS-10-12-0930-RE.

PMID:
30722544
5.

A subcutaneous octreotide hydrogel implant for the treatment of acromegaly.

Gadelha MR, Chieffo C, Bai SA, Hu X, Frohman LA.

Endocr Pract. 2012 Nov-Dec;18(6):870-81. doi: 10.4158/EP11388.OR.

PMID:
22784835
6.

Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.

Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA, Zhou H, Yohrling J, Cohen A, Burggraaf J, Franson K, Davis HM.

Clin Pharmacokinet. 2009;48(9):601-13. doi: 10.2165/11317190-000000000-00000.

PMID:
19725594
7.

A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.

Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J.

J Clin Pharmacol. 2008 Oct;48(10):1197-207. doi: 10.1177/0091270008322907.

PMID:
18812609
8.

N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.

He K, Qian M, Wong H, Bai SA, He B, Brogdon B, Grace JE, Xin B, Wu J, Ren SX, Zeng H, Deng Y, Graden DM, Olah TV, Unger SE, Luettgen JM, Knabb RM, Pinto DJ, Lam PY, Duan J, Wexler RR, Decicco CP, Christ DD, Grossman SJ.

J Pharm Sci. 2008 Jul;97(7):2568-80.

PMID:
17914718
9.

Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.

Qian M, Bai SA, Brogdon B, Wu JT, Liu RQ, Covington MB, Vaddi K, Newton RC, Fossler MJ, Garner CE, Deng Y, Maduskuie T, Trzaskos J, Duan JJ, Decicco CP, Christ DD.

Drug Metab Dispos. 2007 Oct;35(10):1916-25. Epub 2007 Jul 26.

PMID:
17656469
10.

Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine.

Wong H, Grace JE Jr, Wright MR, Browning MR, Grossman SJ, Bai SA, Christ DD.

Xenobiotica. 2006 Dec;36(12):1178-90.

PMID:
17162465
11.

Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.

Li YL, Fevig JM, Cacciola J, Buriak J Jr, Rossi KA, Jona J, Knabb RM, Luettgen JM, Wong PC, Bai SA, Wexler RR, Lam PY.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5176-82. Epub 2006 Jul 25.

PMID:
16870435
12.

Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.

Fevig JM, Cacciola J, Buriak J Jr, Rossi KA, Knabb RM, Luettgen JM, Wong PC, Bai SA, Wexler RR, Lam PY.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3755-60. Epub 2006 May 8.

PMID:
16682200
13.

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.

Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H.

J Clin Oncol. 2005 Apr 20;23(12):2805-12. Epub 2005 Feb 22.

PMID:
15728224
14.

The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application.

Wong H, Grossman SJ, Bai SA, Diamond S, Wright MR, Grace JE Jr, Qian M, He K, Yeleswaram K, Christ DD.

Drug Metab Dispos. 2004 Dec;32(12):1359-69. Epub 2004 Aug 27.

PMID:
15333515
16.

Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.

Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR.

J Med Chem. 2003 Oct 9;46(21):4405-18.

PMID:
14521405
17.

Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles.

Lankford SM, Bai SA, Goldstein JA.

Drug Metab Dispos. 2000 Aug;28(8):981-6.

PMID:
10901710
19.

Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model.

Lankford SM, Plummer D, Hellyer P, Christ DD, Bai SA.

J Cardiovasc Pharmacol. 1997 Nov;30(5):583-90.

PMID:
9388040
20.

Determination of concentration of albendazole sulfoxide in plasma and uterine fluid of heifers.

Piscopo SE, Farin CE, Bai SA.

Am J Vet Res. 1997 Jan;58(1):62-5.

PMID:
8989498
21.

Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats.

Johnson LM, Atkins CE, Keene BW, Bai SA.

J Vet Intern Med. 1996 Sep-Oct;10(5):316-20.

22.
24.

Aging increases pharmacodynamic sensitivity to the hypnotic effects of midazolam.

Jacobs JR, Reves JG, Marty J, White WD, Bai SA, Smith LR.

Anesth Analg. 1995 Jan;80(1):143-8.

PMID:
7802272
25.
26.

Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems.

Theil DR, Stanley TE 3rd, White WD, Goodman DK, Glass PS, Bai SA, Jacobs JR, Reves JG.

J Cardiothorac Vasc Anesth. 1993 Jun;7(3):300-6.

PMID:
8518376
27.

Pharmacokinetics of the enantiomers of verapamil in the dog.

Bai SA, Lankford SM, Johnson LM.

Chirality. 1993;5(6):436-42.

PMID:
8398603
28.

Effects of propranolol on the disposition and negative dromotropic activity of diltiazem in the dog during multiple dosing.

Maskasame C, Lankford SM, Bai SA.

Drug Metab Dispos. 1993 Jan-Feb;21(1):156-61.

PMID:
8095211
30.

Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.

Straw JA, Loo TL, de Vera CC, Nelson PD, Tompkins WA, Bai SA.

J Acquir Immune Defic Syndr (1988). 1992;5(9):936-42.

PMID:
1387417
31.

Pharmacokinetic model-driven infusion of fentanyl: assessment of accuracy.

Glass PS, Jacobs JR, Smith LR, Ginsberg B, Quill TJ, Bai SA, Reves JG.

Anesthesiology. 1990 Dec;73(6):1082-90.

PMID:
2248387
32.

Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog.

Bai SA, Easterling DE, Wilson MJ, Walle UK, Haney CA, Peet NP, Pruett JK, Walle T.

Drug Metab Dispos. 1989 Sep-Oct;17(5):495-505.

PMID:
2573492
33.

Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet.

Fagan TC, Walle T, Oexmann MJ, Walle UK, Bai SA, Gaffney TE.

Clin Pharmacol Ther. 1987 Apr;41(4):402-6.

PMID:
3829577
34.

Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.

Bai SA, Walle UK, Walle T.

J Pharmacokinet Biopharm. 1985 Jun;13(3):229-41.

PMID:
4087163
35.

Pharmacokinetics of digoxin in sheep: limitations of the use of biological half-life for interspecies extrapolation.

Dix LP, Bai SA, Rogers RA, Anderson DL, Riviere JE.

Am J Vet Res. 1985 Feb;46(2):470-2.

PMID:
3994115
37.
38.

Exercise-induced increments in plasma levels of propranolol and noradrenaline.

Hurwitz GA, Webb JG, Walle T, Bai SA, Daniell HB, Gourley L, Boyd Loadholt C, Gaffney TE.

Br J Clin Pharmacol. 1983 Dec;16(6):599-608.

39.

Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin.

Walle UK, Walle T, Bai SA, Olanoff LS.

Clin Pharmacol Ther. 1983 Dec;34(6):718-23.

PMID:
6641085
40.

Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.

Bai SA, Wilson MJ, Walle UK, Walle T.

J Pharmacol Exp Ther. 1983 Nov;227(2):360-4.

PMID:
6631718
41.

Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates.

Walle T, Wilson MJ, Walle UK, Bai SA.

Drug Metab Dispos. 1983 Nov-Dec;11(6):544-9.

PMID:
6140137
42.

Relationships between propranolol plasma protein binding, glycoprotein concentration, and enzyme induction following phenobarbital administration in the dog.

Abramson FP, Robinson D, Bai SA.

Biochem Pharmacol. 1983 Sep 1;32(17):2618-20. No abstract available.

PMID:
6615557
43.

Stereoselective binding of the (-)-enantiomer of propranolol to plasma and extravascular binding sites in the dog.

Bai SA, Walle UK, Wilson MJ, Walle T.

Drug Metab Dispos. 1983 Jul-Aug;11(4):394-5. No abstract available.

PMID:
6137350
45.

Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.

Vu VT, Bai SA, Abramson FP.

J Pharmacol Exp Ther. 1983 Jan;224(1):55-61.

PMID:
6848749
46.

Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade.

Bai SA, Abramson FP.

J Pharmacol Exp Ther. 1983 Jan;224(1):62-7.

PMID:
6129320
47.

Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding.

Bai SA, Abramson FP.

J Pharmacol Exp Ther. 1982 Sep;222(3):589-94.

PMID:
7108766

Supplemental Content

Loading ...
Support Center